Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose / Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana. - In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. - ISSN 0344-5704. - 63(6)(2009), pp. 1161-1163. [10.1007/s00280-008-0858-8]
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Titolo: | Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. | |
Autori: | ||
Data di pubblicazione: | 2009 | |
Rivista: | ||
Citazione: | Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose / Breccia, M; Cilloni, D; Cannella, L; Stefanizzi, Caterina; Tafuri, Agostino; Fama, A; Santopietro, M; Saglio, G; Alimena, Giuliana. - In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. - ISSN 0344-5704. - 63(6)(2009), pp. 1161-1163. [10.1007/s00280-008-0858-8] | |
Handle: | http://hdl.handle.net/11573/32241 | |
Appartiene alla tipologia: | 01a Articolo in rivista |